A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
Azienda Ospedaliero-Universitaria di Parma
Mayo Clinic
National Cancer Institute (NCI)
Cancer Research UK
Stanford University
BerGenBio ASA
Stanford University
Haihe Biopharma Co., Ltd.
Deciphera Pharmaceuticals, LLC
Sumitomo Pharma America, Inc.
Scripps Health
Fore Biotherapeutics
Celgene
Ann & Robert H Lurie Children's Hospital of Chicago
National Cancer Institute (NCI)
Hoffmann-La Roche
Novartis
INSYS Therapeutics Inc
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)